What question did this study set out to answer?

This research aims to evaluate the effectiveness and safety of mesenchymal stem cells for preventing and treating graft-versus-host disease.

The efficacy and safety of MSCs in GVHD prevention and the treatment of SR-aGVHD: a systematic review and meta-analysis of randomized controlled trials

View Full Paper

Ask AI

Bookmark

Authors

Systematic review and meta-analysis identify MSCs' effectiveness in preventing aGVHD and treating SR-aGVHD.

This research aims to evaluate the effectiveness and safety of mesenchymal stem cells for preventing and treating graft-versus-host disease.
Conducted a systematic review and meta-analysis of randomized controlled trials
Searched databases including PubMed, Web of Science, EMBASE, and Cochrane Library
Selected studies based on the PICOS criteria
Assessed risk of bias using appropriate quality tools
Synthesized data to compare outcomes between MSC therapy and controls
MSC administration significantly reduced aGVHD incidence (OR: 0.47; 95% CI 0.32–0.71; p = 0.00003)
MSC therapy also reduced chronic GVHD incidence (OR: 0.50; 95% CI 0.34–0.74; p = 0.0005)
Improved response rates in steroid-refractory aGVHD (OR: 1.50; 95% CI 1.04–2.17; p = 0.03)
Optimal prophylactic outcomes seen with MSC doses of 1 × 10⁶ to < 4 × 10⁶ cells/kg
MSC infusion led to significantly higher remission rates in severe SR-aGVHD compared to conventional treatments.

Wu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark